Search Result

Results for "

Receptor-Tyrosine Kinase

" in MedChemExpress (MCE) Product Catalog:

By Targets:	ADC Antibody (1) Adenosine Kinase (2) Akt (5) Anaplastic lymphoma kinase (ALK) (6) Antibiotic (1) Antibody-Drug Conjugates (ADCs) (2) Apoptosis (26) Autophagy (20) Bacterial (1) Bcl-2 Family (3) Bcr-Abl (2) c-Fms (7) c-Kit (20) c-Met/HGFR (20) c-Myc (1) Cadherin (2) Caspase (3) Discoidin Domain Receptor (5) Drug Derivative (1) Drug Intermediate (1) E3 Ligase Ligand-Linker Conjugates (1) EGFR (8) Endogenous Metabolite (1) Ephrin Receptor (2) ERK (3) FAK (1) Ferlin Family (1) FGFR (30) FLT3 (18) GDNF Receptor (1) HIF/HIF Prolyl-Hydroxylase (1) IGF-1R (1) Insulin Receptor (4) IRE1 (7) Isotope-Labeled Compounds (3) JAK (6) MAPKAPK2 (MK2) (1) MEK (2) Microtubule/Tubulin (2) Mitophagy (7) MMP (3) mRNA (3) mTOR (1) Myosin (1) p38 MAPK (3) PARP (3) PDGFR (47) PERK (1) Phosphatase (1) PI3K (3) PKC (1) Raf (9) Reference Standards (14) RET (12) ROR (2) Ser/Thr Kinase (4) SHP2 (1) Src (6) STAT (5) TAM Receptor (12) Tie (5) TNK1 (2) Trk Receptor (9) VEGFR (48)
By Research Areas:	Cancer (159) Cardiovascular Disease (2) Endocrinology (1) Infection (5) Inflammation/Immunology (16) Metabolic Disease (7) Neurological Disease (8)
Click Chemistry:	Alkynes (1)
Oligonucleotides:	mRNA (3)

177

Inhibitors & Agonists

Screening Libraries

Fluorescent Dyes

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

Natural
Products

120

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Click Chemistry

Oligonucleotides

GMP Molecules

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-10255A

Sunitinib 90+ Cited Publications SU 11248	VEGFR PDGFR IRE1 Mitophagy Autophagy Apoptosis	Cancer
Sunitinib (SU 11248) is a multi-targeted receptor tyrosine kinase inhibitor with IC₅₀s of 80 nM and 2 nM for VEGFR2 and PDGFRβ, respectively . Sunitinib, an ATP-competitive inhibitor, effectively inhibits autophosphorylation of Ire1α by inhibiting autophosphorylation and consequent RNase activation .

HY-15424

5-Iodotubercidin 10+ Cited Publications NSC 113939; 5-ITu	Adenosine Kinase	Cancer
5-Iodotubercidin (NSC 113939), an ATP mimetic, is a potent adenosine kinase inhibitor with an IC₅₀ of 26 nM. 5-Iodotubercidin (NSC 113939) initiates glycogen synthesis in isolated hepatocytes by causing inactivation of phosphorylase and activation of glycogen synthase. 5-Iodotubercidin (NSC 113939) also inhibits CK1, insulin receptor tyrosine kinase, phosphorylase kinase, PKA, CK2, PKC and Haspin .

HY-10255

Sunitinib Malate 90+ Cited Publications SU 11248 Malate	PDGFR VEGFR IRE1 Mitophagy Autophagy Apoptosis	Infection Inflammation/Immunology Cancer
Sunitinib (SU 11248) Malat is a multi-targeted receptor tyrosine kinase inhibitor with IC₅₀s of 80 nM and 2 nM for VEGFR2 and PDGFRβ, respectively . Sunitinib Malat, an ATP-competitive inhibitor, effectively inhibits autophosphorylation of Ire1α by inhibiting autophosphorylation and consequent RNase activation .

HY-13223

Crenolanib 15+ Cited Publications CP-868596	FLT3 PDGFR Autophagy	Cancer
Crenolanib is a potent and selective inhibitor of wild-type and mutant isoforms of the class III receptor tyrosine kinases FLT3 and PDGFRα/β with K_ds of 0.74 nM and 2.1 nM/3.2 nM, respectively.

HY-10407

SU 5402 10+ Cited Publications	VEGFR FGFR PDGFR	Cancer
SU 5402 is a potent multi-targeted receptor tyrosine kinase inhibitor with IC₅₀ of 20 nM, 30 nM, and 510 nM for VEGFR2, FGFR1, and PDGFRβ, respectively.

HY-12044

Cabozantinib S-malate 55+ Cited Publications XL184 S-malate; BMS-907351 S-malate	VEGFR Apoptosis	Cancer
Cabozantinib S-malate (XL184 S-malate) is a potent multiple receptor tyrosine kinases inhibitor that inhibits VEGFR2, c-Met, Kit, Axl and Flt3 with IC₅₀s of 0.035, 1.3, 4.6, 7 and 11.3 nM, respectively.

HY-138696

Zanzalintinib 1 Publications Verification XL092	TAM Receptor c-Met/HGFR VEGFR	Cancer
Zanzalintinib (XL092) is an orally active, ATP-competitive inhibitor of multiple receptor tyrosine kinases (RTKs) including MET, VEGFR2, AXL and MER, with IC₅₀s in cell-based assays of 15 nM, 1.6 nM, 3.4 nM, 7.2 nM respectively. Zanzalintinib exhibits anti-tumor activity. Zanzalintinib has the potential for kinase-dependent diseases and conditions research .

HY-13979

DDR1-IN-1 5 Publications Verification	Discoidin Domain Receptor	Cancer
DDR1-IN-1 is a potent and selective DDR1 receptor tyrosine kinase inhibitor with an IC₅₀ of 105 nM; 4-fold less potent for DDR2 (IC₅₀ = 413 nM) .

HY-18007

ALW-II-41-27 30+ Cited Publications Eph Receptor Tyrosine Kinase inhibitor	Ephrin Receptor	Cancer
ALW-II-41-27 is a Eph family tyrosine kinase inhibitor with an IC₅₀ of 11 nM for Eph2.

HY-12963

Dubermatinib 5+ Cited Publications TP-0903	TAM Receptor Apoptosis	Cancer
Dubermatinib (TP-0903) is a potent and selective Axl receptor tyrosine kinase inhibitor with an IC₅₀ value of 27 nM.

HY-18314

GW 441756 5+ Cited Publications	Trk Receptor Apoptosis	Neurological Disease Cancer
GW 441756 is a potent and specific nerve growth factor (NGF) receptor tyrosine kinases A (TrkA) inhibitor (IC₅₀=2 nM), which eliminates the BmK NSPK-induced neurite outgrowth .

HY-18840

BBT594 2 Publications Verification NVP-BBT594	RET	Cancer
BBT594 is a potent receptor tyrosine kinase RET inhibitor, used for cancer treatment.

HY-10517

Orantinib 5+ Cited Publications SU6668; TSU-68	PDGFR FGFR VEGFR Apoptosis	Cancer
Orantinib (SU6668; TSU-68) is a multi-targeted receptor tyrosine kinase inhibitor with K_is of 2.1 μM, 8 nM and 1.2 μM for Flt-1, PDGFRβ and FGFR1, respectively.

HY-147316

TP-5801	STAT TNK1	Cancer
TP-5801 is an orally active TNK1 (non-receptor tyrosine *kinase) inhibitor (IC₅₀*=1.40 nM), and shows anti-tumor activity .

HY-112452

SU11652	VEGFR FGFR PDGFR c-Kit Apoptosis	Cancer
SU11652 is a potent receptor tyrosine kinase (RTK) inhibitor. SU11652 also inhibits several members of the split kinase family of RTKs, including VEGFR, FGFR, PDGFR, and Kit. SU11652 can be uesd for spontaneous cancers expressing Kit mutations research .

HY-10330

Toceranib SU11654; PHA 291639E	PDGFR VEGFR c-Kit	Cancer
Toceranib phosphate (SU11654 phosphate) is an orally active receptor tyrosine kinase (RTK) inhibitor, and it potently inhibits PDGFR, VEGFR, and Kit with K_is of 5 and 6 nM for PDGFRβ and Flk-1/KDR, respectively. Toceranib phosphate (SU11654 phosphate) has antitumor and antiangiogenic activity, and used in the treatment of canine mast cell tumors .

HY-10501

SU14813 1 Publications Verification	PDGFR VEGFR c-Kit	Cancer
SU14813 is a multi-targeted receptor tyrosine kinases inhibitor with IC₅₀s of 50, 2, 4, 15 nM for VEGFR2, VEGFR1, PDGFRβ and KIT.

HY-P0177

123C4 1 Publications Verification	Ephrin Receptor	Metabolic Disease
123C4 is a potent, selective and competitive agonist of the receptor tyrosine kinase EPHA4, with a K_i value of 0.65 μM .

HY-10185

TG 100572 Hydrochloride 3 Publications Verification	Src VEGFR FGFR PDGFR	Inflammation/Immunology
TG 100572 Hydrochloride is a multi-targeted kinase inhibitor which inhibits **receptor tyrosine kinases** and Src kinases; has IC₅₀s of 2, 7, 2, 16, 13, 5, 0.5, 6, 0.1, 0.4, 1, 0.2 nM for VEGFR1, VEGFR2, FGFR1, FGFR2, PDGFRβ, Fgr, Fyn, Hck, Lck, Lyn, Src, Yes, respectively.

HY-111969

BT18 1 Publications Verification	GDNF Receptor	Neurological Disease
BT18 is a molecule mimic with function similar to glial cell line-derived neurotrophic factor (GDNF) . BT18 shows an effect on GDNF family receptor GFRα1 and RET receptor tyrosine kinase RetA function .

HY-W011266

JNJ-10198409 1 Publications Verification	PDGFR	Cancer
JNJ-10198409 is a relatively selective, orally active, and ATP competitive PDGF-RTK (platelet-derived growth factor receptor tyrosine kinase) inhibitor (IC₅₀=2 nM). It is a dual-mechanism, antiangiogenic, and tumor cell antiproliferative agent. JNJ-10198409 has good activity against PDGFR-β kinase (IC₅₀=4.2 nM) and PDGFR-α kinase (IC₅₀=45 nM) .

HY-145627

Ozuriftamab vedotin BA3021; Anti-ROR2 ADC; CAB-ROR2-ADC	Antibody-Drug Conjugates (ADCs) Microtubule/Tubulin	Cancer
Ozuriftamab vedotin (BA3021), an antibody-drug conjugate (ADC), is a conditionally active biologic (CAB) anti-receptor tyrosine kinase orphan receptor 2 (ROR2) humanized monoclonal antibody Ozuriftamab (HY-145626) conjugated to VcMMAE (HY-15575). Ozuriftamab vedotin has antitumor activities .

HY-10501A

SU14813 maleate	PDGFR VEGFR c-Kit	Cancer
SU14813 maleate is a multi-targeted receptor tyrosine kinases inhibitor with IC₅₀s of 50, 2, 4, 15 nM for VEGFR2, VEGFR1, PDGFRβ and KIT.

HY-176205

Ligritinib AB801	TAM Receptor	Cancer
Ligritinib (AB801) is an orally active AXL receptor tyrosine kinase inhibitor. Ligritinib blocks the downstream signaling pathway by inhibiting the kinase activity of AXL. Ligritinib can be used in cancer research, especially in combination with chemotherapy for non-small cell lung cancer (NSCLC) .

HY-13979A

DDR1-IN-1 dihydrochloride 5 Publications Verification	Discoidin Domain Receptor	Cancer
DDR1-IN-1 dihydrochloride is a potent and selective DDR1 receptor tyrosine kinase inhibitor with an IC₅₀ of 105 nM; 4-fold less potent for DDR2 (IC₅₀ = 413 nM) .

HY-13223A

Crenolanib benzenesulfonate 15+ Cited Publications CP 868596-26	Autophagy PDGFR FLT3	Cancer
Crenolanib benzenesulfonate is a potent and selective inhibitor of wild-type and mutant isoforms of the class III receptor tyrosine kinases FLT3 and PDGFRα/β with K_ds of 0.74 nM and 2.1 nM/3.2 nM, respectively.

HY-10184

TG 100572	Src VEGFR PDGFR FGFR	Cancer
TG 100572 is a multi-targeted kinase inhibitor which inhibits **receptor tyrosine kinases** and Src kinases; has IC₅₀s of 2, 7, 2, 16, 13, 5, 0.5, 6, 0.1, 0.4, 1, 0.2 nM for VEGFR1, VEGFR2, FGFR1, FGFR2, PDGFRβ, Fgr, Fyn, Hck, Lck, Lyn, Src, Yes, respectively.

HY-13016S1

Cabozantinib-d4 XL184-d₄; BMS-907351-d₄	VEGFR c-Met/HGFR c-Kit TAM Receptor FLT3 Apoptosis	Cancer
Cabozantinib-d₄ is deuterium labeled Cabozantinib. Cabozantinib is a potent multiple receptor tyrosine kinases (RTKs) inhibitor that inhibits VEGFR2, c-Met, Kit, Axl and Flt3 with IC50s of 0.035, 1.3, 4.6, 7 and 11.3 nM, respectively.

HY-50055

EtDO-P4	ERK	Cancer
EtDO-P4 is a nanomolar inhibitor of glycosphingolipid (GSL) synthesis. EtDO-P4 suppresses activation of the EGFR-induced ERK pathway and various receptor tyrosine kinases (RTKs). EtDO-P4 can be used for various types of cancer, including Burkitt’s lymphoma .

HY-P9988

Mecbotamab BA301	ADC Antibody TAM Receptor	Cancer
Mecbotamab is a humanized IgG1-κ antibody targeting to AXL receptor tyrosine kinase (AXL). Mecbotamab can serves as a conditionally active biologic (CAB), which can be conjugated with MMAE (HY-15162) via a cleavable linker, to form ADC Mecbotamab vedotin (BA3011) .

HY-P5431

Insulin receptor (1142-1153), pTyr1150	Insulin Receptor	Others
Insulin receptor (1142-1153), pTyr1150 is a biological active peptide. (Peptide used as insulin receptor tyrosine kinase substrate.)

HY-147316A

TP-5801 TFA	STAT TNK1	Cancer
TP-5801 TFA is an orally active TNK1 (non-receptor tyrosine *kinase) inhibitor (IC₅₀*=1.40 nM), and shows anti-tumor activity .

HY-10331S

Regorafenib-d3 BAY 73-4506-d₃	VEGFR Autophagy PDGFR Raf RET	Cancer
Regorafenib-d₃ (BAY 73-4506-d₃) is a deuterium labeled Regorafenib (HY-10331). Regorafenib is a multi-targeted receptor tyrosine kinase inhibitor .

HY-13223R

Crenolanib (Standard) CP-868596 (Standard)	FLT3 PDGFR Autophagy Reference Standards	Cancer
Crenolanib (Standard) is the analytical standard of Crenolanib. This product is intended for research and analytical applications. Crenolanib is a potent and selective inhibitor of wild-type and mutant isoforms of the class III receptor tyrosine kinases FLT3 and PDGFRα/β with Kds of 0.74 nM and 2.1 nM/3.2 nM, respectively.

HY-153012

Axl/Mer/CSF1R-IN-1	TAM Receptor c-Fms	Cancer
Axl/Mer-IN-1 (Compound 1) is an Axl/Mer receptor tyrosine kinase (Axl/Mer RTK) and CSF1R inhibitor with K_ds of <0.1 μM .

HY-N11675

5-Hydroxy-TSU-68	Endogenous Metabolite	Cancer
5-Hydroxy-TSU-68 (compound M1) is the 5-hydroxylated indolinone derivative of TSU-68. TSU-68 is an anticancer agent that inhibits angiogenic receptor tyrosine kinases .

HY-18316

RO495	JAK	Inflammation/Immunology
RO495 is a potent inhibitor of non-receptor tyrosine-protein kinase 2 (TYK2 kinase) .

HY-101756

SDZ281-977 SDZ-LAP 977	EGFR	Cancer
SDZ 281-977 is a derivative of the EGF receptor tyrosine kinase inhibitor Lavendustin A.

HY-159503

Segigratinib 3D185 free base; HH185 free base	FGFR c-Fms	Cancer
Segigratinib is a fibroblast growth factor receptor tyrosine kinase inhibitor, with antineoplastic effect .

HY-13892

Dovitinib dilactic acid CHIR-258 dilactic acid; TKI258 dilactic acid	VEGFR	Cancer
Dovitinib (dilactic acid) is an orally active inhibitor of VEGF kinase. Dovitinib (dilactic acid) inhibits receptor tyrosine kinases (RTKs) involved in solid and hematologic cancers and tumor angiogenesis .

HY-101962

HNMPA	Insulin Receptor	Metabolic Disease
HNMPA is a membrane impermeable insulin receptor tyrosine kinase inhibitor. HNMPA inhibits serine and tyrosine autophosphorylation by the human insulin receptor. HNMPA has no effect on protein kinase C or cyclic AMP-dependent protein kinase activities

HY-172228

RPR-101511	PDGFR	Cardiovascular Disease
RPR-101511 is a 3-substituted quinoline derivative. RPR-101511 is a PDGF receptor tyrosine kinase inhibitor (IC₅₀: 0.001-0.02 μM) .

HY-113876

2-Methyl-3-phenylquinoxaline	PDGFR	Cancer
2-Methyl-3-phenylquinoxaline (compound 38) is a potent platelet-derived growth factor receptor tyrosine kinase (PDGF-RTK) inhibitor with modest inhibitory activity against PDGFR kinase in intact cells (IC₅₀ greater than 100 μM) .

HY-P1803

Protein Kinase C Peptide Substrate PKCε; PRKCE ; Peptide Epsilon	PKC	Neurological Disease Inflammation/Immunology Endocrinology
Protein Kinase C Peptide Substrate is targeted to a specific cellular compartment in a manner dependent on second messengers and on specific adapter proteins in response to extracellular signals that activate G-protein-coupled receptors, tyrosine kinase receptors, or tyrosine kinase-coupled receptors. Protein Kinase C Peptide Substrate then regulates various physiological functions including the activation of nervous, endocrine, exocrine, inflammatory, and immune systems .

HY-P10569

Biotin HER-2 substrate peptide	EGFR	Cancer
Biotin HER-2 substrate peptide is a substrate of Her4 and Her2/neu tyrosine kinase with a K_m value of 60 μm for Her2/neu kinase domain .

HY-E70869

TRKA(NTRK1) Recombinant Human Active Protein Kinase	Trk Receptor	Neurological Disease
TRKA (also named NTRK1) is a potential new member of the tyrosine kinase gene family. TRKA is a receptor tyrosine kinase that is phosphorylated in response to NGF. A single transmembrane domain divides TRKA into an extracellular domain, important for NGF binding, and an intracellular tyrosine kinase domain, important for signal transduction. TRKA(NTRK1) Recombinant Human Active Protein Kinase is a recombinant TRKA(NTRK1) protein that can be used to study TRKA(NTRK1)-related functions .

HY-E70763

PDGFRalpha T674I Recombinant Human Active Protein Kinase	PDGFR	Cancer
PDGFRalpha is a receptor tyrosine kinases that stimulate cell survival, proliferation and motility. Upon PDGF binding, the receptor dimerizes and undergoes a conformational change, which activates the kinase domain. PDGFRalpha T674I is a mutant of PDGFRalpha. PDGFRalpha T674I Recombinant Human Active Protein Kinase is a recombinant PDGFRalpha T674I protein that can be used to study PDGFRalpha T674I-related functions .

HY-160689

GW694590A UNC10112731	c-Myc c-Kit Discoidin Domain Receptor PDGFR	Others
GW694590A (UNC10112731) is a MYC protein stabilizer that increases endogenous MYC protein levels. GW694590A also targets receptor tyrosine kinases, inhibiting DDR2, KIT and PDGFRα by 81% at 1 μM. , 68% and 67%. GW694590A is a protein kinase inhibitor across ATP-dependent and -independent luciferases with potential effects on the Fluc reporter gene .

HY-E70823

FGFR2 N549K Recombinant Human Active Protein Kinase	FGFR	Cancer
FGFR2 is a receptor tyrosine kinase that is involved in many human cancers such as intrahepatic cholangiocarcinomas and hepatocellular carcinomas. FGFR2 N549K is a mutant of FGFR3. FGFR2 N549K Recombinant Human Active Protein Kinase is a recombinant FGFR4 N535K protein that can be used to study FGFR4 N535K-related functions .

HY-10255C

Sunitinib glucuronate 90+ Cited Publications SU 11248 glucuronate	PDGFR VEGFR IRE1 Mitophagy Autophagy Apoptosis	Cancer
Sunitinib (SU 11248) glucuronate is a multi-targeted receptor tyrosine kinase inhibitor with IC₅₀s of 80 nM and 2 nM for VEGFR2 and PDGFRβ, respectively . Sunitinib glucuronate, an ATP-competitive inhibitor, effectively inhibits autophosphorylation of Ire1α by inhibiting autophosphorylation and consequent RNase activation .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N11675

5-Hydroxy-TSU-68	Alkaloids Monophenols Pyrrole Alkaloids Phenols Endogenous metabolite Source Classification	Endogenous Metabolite
5-Hydroxy-TSU-68 (compound M1) is the 5-hydroxylated indolinone derivative of TSU-68. TSU-68 is an anticancer agent that inhibits angiogenic receptor tyrosine kinases .

HY-N12041

Axl-IN-16	Natural Products Microorganisms Source Classification	TAM Receptor HIF/HIF Prolyl-Hydroxylase
Axl-IN-16 is a dual inhibitor of Axl/HIF. Axl-IN-16 induces fruiting body formation of Flammulina velutipes. Axl-IN-16 inhibits hypoxia-inducible factor activity and receptor tyrosine kinase expression .

Cat. No.	Product Name	Chemical Structure

HY-13016S

Cabozantinib-d6
Cabozantinib-d₆ is the deuterium labeled Cabozantinib. Cabozantinib is a potent multiple receptor tyrosine kinases (RTKs) inhibitor that inhibits VEGFR2, c-Met, Kit, Axl and Flt3 with IC₅₀s of 0.035, 1.3, 4.6, 7 and 11.3 nM, respectively .

HY-13016S1

Cabozantinib-d4
Cabozantinib-d₄ is deuterium labeled Cabozantinib. Cabozantinib is a potent multiple receptor tyrosine kinases (RTKs) inhibitor that inhibits VEGFR2, c-Met, Kit, Axl and Flt3 with IC50s of 0.035, 1.3, 4.6, 7 and 11.3 nM, respectively.

HY-10331S

Regorafenib-d3
Regorafenib-d₃ (BAY 73-4506-d₃) is a deuterium labeled Regorafenib (HY-10331). Regorafenib is a multi-targeted receptor tyrosine kinase inhibitor .

HY-10255AS1

Sunitinib-d4
Sunitinib-d₄ is the deuterium labeled Sunitinib. Sunitinib (SU 11248) is a multi-targeted receptor tyrosine kinase inhibitor with IC₅₀s of 80 nM and 2 nM for VEGFR2 and PDGFRβ, respectively . Sunitinib, an ATP-competitive inhibitor, effectively inhibits autophosphorylation of Ire1α by inhibiting autophosphorylation and consequent RNase activation .

HY-10255AS

Sunitinib-d10
Sunitinib-d₁₀ (SU 11248-d₁₀) is a deuterium labeled Sunitinib. Sunitinib is a multi-targeted receptor tyrosine kinase inhibitor with IC₅₀s of 80 nM and 2 nM for VEGFR2 and PDGFRβ, respectively . Sunitinib, an ATP-competitive inhibitor, effectively inhibits autophosphorylation of Ire1α by inhibiting autophosphorylation and consequent RNase activation .

HY-10330S

Toceranib-d8
Toceranib-d₈ is the deuterium labeled Toceranib. Toceranib (SU11654) is an orally active receptor tyrosine kinase (RTK) inhibitor, and it potently inhibits PDGFR, VEGFR, and Kit with Kis of 5 and 6 nM for PDGFRβ and Flk-1/KDR, respectively. Toceranib (SU11654) has antitumor and antiangiogenic activity, and used in the treatment of canine mast cell tumors .

HY-10331S1

Regorafenib-13C,d3
Regorafenib- ¹³C,d₃ is the ¹³C- and deuterium labeled Regorafenib. Regorafenib (BAY 73-4506) is a multi-targeted receptor tyrosine kinase inhibitor with IC50s of 13/4.2/46, 22, 7, 1.5 and 2.5 nM for VEGFR1/2/3, PDGFRβ, Kit, RET and Raf-1, respectively.

HY-W706452

Cabozantinib-d4 S-malate
Cabozantinib-d₄ (S-malate) (XL184-d₄ (S-malate); BMS-907351-d₄ (S-malate)) is the deuterium labeled Cabozantinib (S-malate) (HY-12044). Cabozantinib S-malate (XL184 S-malate) is a potent multiple receptor tyrosine kinases inhibitor that inhibits VEGFR2, c-Met, Kit, Axl and Flt3 with IC₅₀s of 0.035, 1.3, 4.6, 7 and 11.3 nM, respectively.

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-10407G

SU 5402	VEGFR EGFR PDGFR	Cancer
SU 5402 (GMP) is SU 5402 (HY-10407) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. SU 5402 is a potent multi-targeted receptor tyrosine kinase inhibitor with IC₅₀ of 20 nM, 30 nM, and 510 nM for VEGFR2, FGFR1, and PDGFRβ, respectively .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Species:	Human (76) Rhesus Macaque (10) Rat (13) Mouse (18) Cynomolgus (3) Canine (2)
Tag:	SUMO (1) His (78) Strep (3) Tag Free (6) Avi (13) Myc (1) GST (16) Flag (3) Fc (34)
Source:	HEK293 (85) sf9 insect cells (6) P. pastoris (1) Sf9 insect cells (25) E. coli (3)


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Host:	Mouse (22) Rabbit (42)
Reactivity:	Human (64) Rat (20) Mouse (24) Monkey (4)
Application:	IHC-P (40) ICC/IF (36) mIHC (1) IF-Tissue (9) IP (21) IHC-F (14) WB (61) FC (7) ELISA (19)
Isotype:	IgG (44) IgG1 (12) IgG1,IgG/Kappa (1) IgG2a (1) IgG2b (1)
Conjugation:	Non-conjugated (64) Biotin (16)
Clonality:	Polyclonal (2) Monoclonal (38) Recombinant (15)
Modification:	Phosphorylated (7) Unmodified (34)


Products	In-stock - + Add to Cart
Cat. No.
Host
Reactivity
Application
Dilution Ratio
Molecular Weight
Conjugation
Clonality
Immunogen
Appearance
Isotype
Gene ID
SwissProt ID
Purity
Formulation
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Receptor-Tyrosine Kinase

Inhibitors & Agonists

Screening Libraries

Fluorescent Dyes

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

NaturalProducts

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Click Chemistry

Oligonucleotides

GMP Molecules

Natural
Products